Close Menu

NEW YORK – TargetCancer Foundation said on Wednesday that it initiated the TCF-001 TRACK study, a prospective clinical trial that will enroll 400 patients with rare cancers such as cholangiosarcoma or cancers of unknown primary.

TargetCancer Foundation is the study's sponsor, and Bayer is also a founding supporter. Roche subsidiary Foundation Medicine, which markets tissue and blood-based next-generation sequencing panels for guiding cancer treatment, is also a collaborator.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.


NTRK fusions are oncogenic drivers in a variety of tumors.

Sponsored by

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Sponsored by

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.


In non-small cell lung cancer (NSCLC), early detection of emerging resistance mutations such as EGFR T790M is important in order to determine the appropriate targeted therapeutic strategy.